Health consciousness increases with economic growth.
Print Psoriasis is a common chronic skin disorder affecting approximately 9. It is also associated with several comorbidities such as obesity, hypertension, psoriatic arthritis, depression, and diabetes. Psoriasis is characterized by skin flares and inflammation that vary in severity, from minor localized patches to substantial body surface involvement.
For such patients, psoriasis is often a debilitating condition impacting their quality of life and psychological well-being. Over the past decade, biologics have altered the landscape in the management of moderate to severe psoriasis by achieving improved skin clearance, control of symptoms and quality of life for hundreds of thousands of individuals affected.
While these medications are moderately effective, they suppress the entire immune system, requiring clinicians to do routine laboratory monitoring because of increased liver and renal toxicity, hematologic side effects, and myelosuppression. Systemic therapies are also contraindicated in various patient subpopulations, such as pregnant women, nursing mothers and individuals with liver or kidney disease.
Thus a huge unmet need existed for therapies that were safe for long-term use, offered efficacy in moderate to severe psoriasis patients, and provided an alternative to patients who were refractory or contraindicated to conventional systemics.
Psoriasis is linked to pathogenesis caused by dysregulation of T-cell-dependent immune response, as well as hyperproliferation of keratinocytes, the predominant cell type on the outer layer of skin.
Biologics target the cytokines usually upregulated as a result of the abnormal immune response. Currently, there are six FDA-approved biologics for the treatment of psoriasis belonging to three separate drug classes: Two biologics, Amevive alefacept, Astellas Pharma and Raptiva efalizumab, Merck Seronoinitially approved for psoriasis in were withdrawn from the market in and respectively due to insufficient response in patients on Amevive and safety concerns with Raptiva.
Since the availability of Stelara inthe total U. The latest wave of biologics is the IL inhibitors with the first-in-class, Cosentyx secukinumab, Novartis launching in followed by Taltz ixekizumab, Eli Lilly in early These drugs specifically target IL, a cytokine involved directly in skin inflammation.
IL inhibitors are highly efficacious and offer clinical improvements on stringent end points such as PASI 90 and PASI total skin clearance over previous therapies.
Thus, the psoriasis biologics market will become more competitive with many drug classes competing for the same moderate to severe patient population. Immune and inflammatory pathways play a key role in these dermatological conditions, and several biologics initially developed to treat autoimmune diseases such as psoriasis, rheumatoid arthritis, and allergic asthma have proven effective in some of these dermatological diseases.
Recently, Humira was approved for moderate to severe form of hidradenitis suppurativa. Likewise, chronic idiopathic urticaria, a form of chronic urticaria caused by an autoimmune reaction, saw the approval of Xolair, a biologic that reduces an IgE-sensitized allergic immune response in asthma.
Atopic dermatitisa common skin condition, currently has an underserved severe patient population, which is similar to the unmet need that existed in psoriasis before the entry of biologics. Given the demonstrated efficacy and safety profile of dupilumab as well as physician enthusiasm towards the agent, we can assume that the drug will experience rapid uptake and exponentially expand the dollar value of the atopic dermatitis market before launch of subsequent biologics.
Clinical data for tralokinumab and lebrikizumab are limited, therefore it is too early to predict the extent of impact of these IL inhibitors on the atopic dermatitis market.Global Skincare Market to Reach $ Billion by by Sarah Schmidt, on March 22, According to a recent report by Lucintel, the worldwide skincare products industry is forecast to reach $ billion by , with opportunities in anti-aging, body lotion, sun protection, and multi-functional skin cream.
Beauty and personal care sees positive growth overall in In , beauty and personal care recorded an improved performance, posting faster retail volume and current value sales growth, compared with Categories of cosmetics discussed in this report include skin and sun care products, hair care products, deodorants, makeup and color cosmetics and fragrances.
Skin care category is one of the most technically advanced, . Naturex, the French-based botanicals giant that recently acquired the ingredients business of Spanish company, Natraceutical Group, will earn €m in – up from its income of €m, as it announced details of the deal.
We have more than 5, employees in China, it’s a market we have participated in for a long time.” Online platform perks Despite all the uncertainty, the Estée Lauder Cos will continue to expand growth and footprint in China especially online on Tmall where it has experienced considerable success.
In , total U.S. sales for the men's personal care market hit $ billion, up percent from and 19 percent from , making it one of the fastest-growing segments of the beauty industry.